News

Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.

Company has received VLAIO grant of € 250.000 for research and development of LYO-ID for freeze-dried medicinal products.

The financing will fuel Strata's tumor sequencing operation and implementation of the Strata trial.

Financing will be used to support programmes focused on degenerative kidney disease, major inflammatory disease and cancer.

Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.

Findings from TSRI reveal human proteins are better drug targets than previously thought.

With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?

Companies launching an initiative to find new epigenetic drug targets in respiratory disease.

KalVista to become a wholly owned subsidiary of Carbylan, and KalVista shareholders to become majority owners of Carbylan upon the closing of the transaction.

Lonza to continue sponsorship of horseshoe crab conservation initiatives by the Ecological Research & Development Group (ERDG).